Estrogens are potent mitogens for some target organs, such as the uterus, and cancers that develop in this organ might be linked to the proliferative action of these hormones. However, the mechanism by which estrogens influence the cell cycle machinery is not known. We found that a null mutation for the insulin receptor substrate (IRS)-1, a docking protein that is important for IGF1 signaling, compromised hormoneinduced mitosis in the uterine epithelium; BrdU incorporation was not affected. This selective effect on mitosis was associated with a reduction in uterine cyclin B-associated kinase activity; cyclin A-associated kinase activity was not changed. The null mutation also reduced the extent of hormone-induced phosphorylation of endogenous uterine histone H1, as determined with phospho-specific antiserum. Uterine epithelial cyclin dependent kinase (cdk)1 was induced in response to hormone, but the level of the kinase protein, as determined by immunoblotting, was noticeably less in the irs1 null mutant than that in the wild-type (WT) mouse, especially around the time of peak mitosis (24 h). Since IRS-1 binds/activates phosphatidylinositol 3-kinase (PI3K), the absence of this docking protein could impair signaling of a known pathway downstream of AKT that stimulates translation of cell cycle components. Indeed, we found that phosphorylation of uterine AKT (Ser473) in irs1 null mutants was less than that in WTs following treatment. Based on earlier studies, it is also possible that an IGF1/IRS-1/PI3K/AKT pathway regulates posttranslational changes in cdk1. This model may provide insights as to how a growth factor pathway can mediate hormone action on cell proliferation.
Introduction
It is well known from laboratory studies of rodents that estradiol (E 2 ) is a potent mitogen for uterine luminal and glandular epithelial cells (Tong & Pollard 2002) . This mitotic action extends to other congeners of E 2 and may contribute to the increased risk of endometrial carcinoma observed in postmenopausal females provided with estrogen replacement therapy (Gambrell et al. 1983) . The proliferative response to E 2 occurs naturally during the ovarian cycle and during early pregnancy. Hormone interaction with the uterine estrogen receptor-a (ERa) is apparently essential for this action since ovariectomized ERa knockout (aERKO) mice exhibit negligible uterine cell DNA synthesis or proliferation in response to E 2 (Couse et al. 1995) . Injection of E 2 into the ovariectomized rodent increases both the expression of cell cyclins and the activation of cyclin-dependent kinases (cdk). Transcripts for uterine cyclins D (D1-D3), E, A, and B increase, with each cyclin having a specific temporal pattern following estrogen exposure (Altucci et al. 1997 , Tong & Pollard 1999 . In mammalian cells, cyclin A is reported to function during S phase, as well as during the G 2 /M transition, whereas cyclin B controls entry into mitosis (Minshull et al. 1990 , Nurse 1990 . There is limited knowledge of the local pathways that link activation of the estrogen receptor with the uterine epithelial cell cycle machinery. For over two decades, investigators have considered the notion that hormone-induced growth factors can serve as mediators of cell proliferation. In this regard, experimental evidence is compiling that supports a functional role for the insulin-like growth factor 1 (IGF1) in estrogeninduced proliferation of uterine epithelial cells. E 2 is known to increase the level of IGF1 transcripts in the uterus of some mammals. For instance, IGF1 mRNA increases by 14-fold in the uterus of the ovariectomized rat as early as 6 h after treatment with E 2 (Murphy et al. 1987) . This elevation of the uterine IGF1 ligand leads to activation of the IGF1 receptor and downstream signaling pathways in the uterus (Richards et al. 1996 , Klotz et al. 2000 . Other studies show that the insulin receptor substrate-1 (IRS-1), which functions as a primary substrate for the insulin and IGF1 receptors, is critical for the mitogenic response of these factors (Waters et al. 1993 , Rose et al. 1994 , Bruning et al. 1997 . The omission of IRS-1 in embryonic fibroblasts by null mutation results in a marked reduction in IGF1-stimulated cell proliferation and phosphatidylinositol 3-kinase (PI3K) activity (Bruning et al. 1997) . In situ hybridization studies suggest that the interaction of IGF1 with the uterine epithelial IGF1 receptor occurs through a paracrine-type mechanism, with IGF1 originating in proximal stromal cells (Baker et al. 1996 , Cooke et al. 1997 . A complex containing the IGF1R, IRS-1, and PI3K occurs in uterine extracts of mice treated with E 2 or IGF1 (Richards et al. 1998) . Formation of this hormone-induced complex is severely compromised in aERKO mice (Klotz et al. 2000) and also in IGF1 m/m mice (Richards et al. 1998) , which have a deficiency in IGF1 (Lembo et al. 1996) .
It is well known that IGF1 can stimulate proliferation of a variety of cells in vitro (Lowe 1991) . This growth factor was originally referred to as a 'G 1 progression factor' as an outcome of these earlier studies (Leof et al. 1982 , Campisi & Pardee 1984 . However, a more recent investigation of cell cycle kinetics in fibroblasts derived from igf1 K/K null mice reveals a large increase in the duration of the G 2 /M phase when compared with that of wild-type (WT) cells (Sell et al. 1994) . Moreover, when intact igf1 K/K null female mice are treated with E 2 , the proportion of uterine epithelial cells in the G 1 and S phases by 20 h is not different between WT and mutant mice; however, cell number and mitotic figures are markedly reduced in the igf1 K/K null mice (Adesanya et al. 1999) . This is the direct evidence that IGF1 provides a mitogenic stimulus in the uterus in response to E 2 and does so by influencing transit time through G 2 /M, rather than G 1 .
The major goal of this study is to identify components of the cell cycle in the uterus that are regulated by the hormoneinduced IGF1 signaling pathway. To achieve this, we use the uterine epithelium of hormone-treated ovariectomized mice as an experimental model (Fagg et al. 1979) . This model permits analysis of signaling and cell cycle proteins in the uterine epithelium, while providing the permissive microenvironment for E 2 to stimulate cell proliferation (Cooke et al. 2002) . Since adult igf1 K/K null mutant mice are extremely small and can exhibit a high frequency of neonatal lethality (Liu et al. 1993) , irs1 K/K null mutants (Araki et al. 1994) were selected for most of the experiments. As described above, the uterus of the irs1 K/K mouse should have a compromised IGF1 signaling pathway. Our initial experiments used igf1 K/K mice to establish that this ligand is critical for E 2 -stimulated association of PI3K (p85) with IRS-1. Following this, we sought to determine whether irs1 K/K null mutants exhibit compromised mitosis in the uterine epithelium in response to E 2 , as was previously observed with igf1 K/K null mutants (Adesanya et al. 1999) . Finally, we attempted to identify what component(s) of the cell cycle might be regulated by the IGF1/IRS-1 pathway. Our findings indicate that the IGF1/IRS-1 pathway contributes to the mitogenic action of E 2 by stimulation of cyclin B-associated cdk1 kinase. This finding may have broad implications with regard to the mechanism by which IGF1 provides a stimulus for cell proliferation in various tissues or neoplasias.
Materials and Methods
Mice, treatments, and tissue collection IRS-1 WT (irs1 C/C ) and IRS-1 null mutant (irs1
) mice on a C57Bl/6!129Sv background were generated in our laboratory from heterozygous IRS-1 breeding pairs obtained from Taconic (Germantown, NY, USA) with the permission of Dr Ronald Kahn ( Joslin Diabetes Center, Boston, MA, USA). Null mutants were also generated by breeding irs1 K/K males with irs1 C/K females. The weight of female irs1
mice was w70% that of the corresponding WTs. IGF1 WT (igf1
) and IGF1 null mutant (igf1
) mice were generated from heterozygous IGF1 breeding pairs (MF1!129/Sv hybrids) provided by Dr Argiris Efstratiadis (Columbia University, New York, NY, USA). Tail genomic DNA was screened by PCR to determine the genotype. All of the WT, irs1
, and igf1 K/K mice were ovariectomized at 8-13 weeks of age. Procedures for surgery, treatments, and euthanasia were conducted in compliance with the guidelines of the NIEHS, National Institutes of Health Animal Care and Use Committee.
To assess 5-bromo-2-deoxyuridine (BrdU) incorporation, ovariectomized WT and irs1 K/K mice (nZ8 per group) were treated with E 2 (0 . 08 mg/g) or vehicle (4% v/v ethanol PBS) s.c. and killed after 18 h; BrdU (Sigma, 0 . 1 mg/g i.p.) was injected 2 h before euthanasia. For mitosis experiments, mice (nZ4 per group) were killed 22 h after hormone treatment; the anti-mitotic compound demecolcine (Colcemid, Sigma, 5 mg/g i.p.) was injected 2 h before euthanasia. Uteri were excised, and a 5 mm long transverse section in the middle of each horn was taken and immersed in 10% neutral-buffered formalin. Paraffin sections were prepared by standard procedures. BrdU was detected in sections with a rat antiBrdU monoclonal antibody that was part of a Vector kit (no. PK4004). All mice were treated with hormone no earlier than 14 days after ovariectomy. Apoptotic cells were identified in uterine sections with a TACS 2 TdT (TBL) In Situ Apoptosis Detection kit (Trevigen, Gaithersburg, MD, USA) according to the manufacturer's instructions; negative and positive control slides were included in the kit.
Epithelial cell extracts
Mice were treated with hormone as described above and euthanized at various time points after treatment. The specific intervals (up to 48 h) following treatment for the different experiments are shown in the figures. For the 0 time point, mice were treated with 4% ethanol PBS and immediately killed. Uterine epithelial cells were removed as described previously (Fagg et al. 1979 , Tong & Pollard 1999 . Briefly, uteri were slit lengthwise and placed in 15 ml tissue culture tubes with chilled extraction buffer (1% Triton X-100, 150 mM NaCl, 1 mM Na 3 VO 4 , 1 mM NaF, 50 mM Na 2 MO 4 , 20 mg/ml aprotinin, 20 mg/ml leupeptin, and 4 mg/ml 4-amido-phenylmethylsulfonyl fluoride in 50 mM Tris-HCl, pH 7 . 4). A volume of 580 and 400 ml buffer was used for each WT and irs1 K/K uterus respectively. The uteri were agitated in the presence of seven glass beads (3 . 0 mm diameter) on a Vortex-Genie mixer (30 s on/30 s off) for a total of 5 min. The resulting cell suspension was drawn off and then disrupted ultrasonically (3!5 s bursts) followed by brief centrifugation. The supernatant was transferred to a microfuge tube and stored at K80 8C. Protein concentration was determined with a Pierce BCA assay kit (Pierce Chemical, Rockford, IL, USA) with bovine albumin (2 mg/ml) as a standard.
Western immunoblotting and immunoprecipitation
To remove endogenous IgGs prior to immunoprecipitation, aliquots of supernatants were cleared by incubating with 100 ml washed protein A-Sepharose (CL-4B, Amersham Pharmacia Biotech) for 30 min at 4 8C. For immunoprecipitation, the cleared aliquots (300-450 mg protein) were incubated with 5 mg antibody for 2 h at 4 8C. After incubation with the antibody, the supernatants were incubated with the protein A-Sepharose for an additional 2 h at 4 8C. Antibody/protein A-Sepharose pellets were washed three times with the extraction buffer and subjected to kinase assays or boiled for 5 min in Laemmli sample buffer. After boiling, the precipitates were stored at K20 8C. Aliquots of mouse uterine epithelial cell extracts or immunoprecipitates were boiled for an additional 2 min, subjected to SDS-PAGE, and then transferred to polyvinylidene fluoride (Immobilon-P) membrane (Millipore, Bedford, MA, USA). The membrane was blocked with either 5% bovine albumin/Tris-buffered saline (TBS) with 0 . 1% Tween 20 or 5% nonfat dry milk/PBS and incubated with a dilution of specific antibody. For cdk1, where cytokeratin 18 was used as a loading control, the membrane was cut just above the 37 kDa protein marker. The lower portion (cdk1) was blocked with 1% BSA/TBS-Tween, and the upper portion (cytokeratin 18) was blocked with 5% nonfat dry milk/PBS. Antibodies (catalog number) to IRS-1 (06-248), p85 (06-195), cdk1 (06-141) , and cdk2 (05-596) were purchased from Upstate (Temecula, CA, USA); antibodies to cyclin A (sc-596), cyclin B1 (sc-595), and cytokeratin 18 (sc-28264) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA); antibodies to AKT (9272) and phospho-AKT (Ser473) (9271) were from Cell Signaling Technology (Beverly, MA, USA).
Each membrane was then incubated with a HRP-conjugated donkey anti-rabbit (NA9340) (Amersham Biosciences) or goat anti-mouse IgG secondary antibody (A3682) from Sigma.
Immunoreactive proteins were detected using enhanced chemiluminescence (Amersham Pharmacia Biotech).
Six trials were used to obtain immunoblots of uterine cdk1 and cdk2 for up to 30 h after E 2 treatment of WT versus irs1 K/K mice. Four trials were used to examine uterine cdk1 levels in both the groups 24 h after E 2 treatment with cytokeratin 18 as a loading control. Four trials were also used to analyze p-AKT/AKT in both the groups in a time-course study. In these experiments, different extracts were analyzed for each trial. Densitometric scans of immunoblot bands were made with an Alpha Innotech FluorChem FC2 Imaging System.
Microarray analysis
Fold changes in mouse uterine cdk1 and cdk2 transcripts following treatment with E 2 were retrieved from the microarray data offered by Sylvia C Hewitt and Dr Bonnie Deroo (NIEHS, NIH). Details of the experimental design have been published (Hewitt et al. 2003) , and the repository for the microarray data is accessible at NCBI's Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/ geol/); accession numbers GSE4664 and GSE4615.
Quantitative real-time PCR
Uteri were obtained from control (0 h; nZ4 for each group) and estrogen-treated mice (24 h; nZ6 for each group). Each uterus removed was immediately placed on ice in a tube containing 1 . 5 ml RNAlater Stabilization Reagent (Ambion, Austin, TX, USA). RNA was extracted with the RNeasy Mini kit (Qiagen) according to the manufacturer's instructions. Uteri were transferred to the RLT buffer (0 . 6 ml per uterus) containing b-mercaptoethanol (15 ml/ml), and homogenized with an Omni Model TH-115 hand-held homogenizer (7 mm sawtooth probe with three bursts at full power, each at ten seconds). RNA isolation was followed by a DNA removal step with DNase I. One microgram total RNA was then reverse transcribed using a Gene Amp PCR 29 System 9700 (Applied Biosystems, Foster City, CA, USA) and the SuperScript First-Strand Synthesis System 30 (Invitrogen).
Quantitative real-time PCR was performed with the Power SYBR Green PCR Master Mix (Applied Biosystems) on a Bio-Rad iCycler (Bio-Rad). The primers for mouse cdk1 were 5 0 -GGA-CCT-CAA-GAA-GTA-CCT-GGA-C-3 0 (forward) and 5 0 -CCC-TGG-AGG-ATT-TGG-TGT-AAG-3 0 (reverse). The primers for mouse actin were 5 0 -TGA-CAG-GAT-GCA-GAA-GGA-GA-3 0 (forward) and 5 0 -CGC-TCA-GGA-GGA-GCA-ATG-3 0 (reverse). The cDNAs were amplified for 40 cycles (95 8C/10 min/ (95 8C/15 s/60 8C/30 s)). Controls included the omission of template or primers. Melt curves of both the amplicons indicated the presence of a single product and the absence of primer-dimer formation. Relative quantitation of cdk1 expression was determined by the comparative C t method (Pfaffl 2001) with actin as the endogenous reference gene.
Real-time PCR efficiencies for the cdk1 (EZ1 . 97) and actin (EZ1 . 98) were determined from the Q5 Optical System Software (Bio-Rad).
Cyclin-associated kinase assay
Uterine epithelial extracts were prepared as described above and stored at K80 8C. Equal amounts of WT and KO extracts (w400 mg protein) were diluted to 0 . 5 ml with the extraction buffer. After preclearing the sample with protein A-Sepharose, 5 mg anti-cyclin B (Upstate) or anti-cyclin A (Santa Cruz) were reacted with the sample for 2 . 5 h. Protein A-Sepharose was added, and the immunoprecipitates collected were washed three times with the extraction buffer and then three times with the cdk1/cdk2 kinase assay buffer (20 mM 3-(N-morpholino)propanesulfonic acid, pH 7 . 2, 25 mM glycerol phosphate, 5 mM EGTA, 1 mM sodium orthovanadate, and 1 mM dithiothreitol). The kinase reaction was carried out according to the instructions of the cdk1/cdk2 kinase assay kit (Upstate). Kinase activity of the immunoprecipitate was carried out in the assay buffer containing 10 mCi [g-32 P]ATP (3000 Ci/mmol), 90 mM ATP, and 14 mM MgCl 2 . Histone H1 (0 . 4 mg/ml) was the exogenous substrate. The mixture was incubated for 10 min at 30 8C. The assay was stopped by placing the reaction tubes on ice and adding gel sample loading buffer. Sample proteins were separated on 4-20% Tris Ready Gels (Bio-Rad) and transblotted to Immobilon-P membrane. Five separate trials, each with different uterine extracts, were used for the kinase assays. Detection was made by autoradiography and phosphoimaging (Storm 860 Molecular Imager).
In situ histone (H1) phosphorylation
Nuclei were isolated from whole uteri following homogenization in a detergent-containing buffer, as described previously (Archer et al. 1991) . Nuclei were resuspended in 0 . 2 M H 2 SO 4 and proteins in the soluble fraction precipitated with 5 volumes of ethanol. Ten micrograms isolated histones were separated by SDS-PAGE and transferred onto polyvinylidene fluoride membrane. Immunoblotting procedures were similar to those described above. The membrane was probed with antibodies (1-2 mg/ml) developed in rabbits against mouse H1.3 amino acids 15-27 containing a phosphate at Thr18 (Deterding et al. 2008) . A test of the antibody against chromatographically purified H1 isoforms revealed recognition of only H1.3 and H1.4 isoforms in mouse cells; the antibody did not detect an H1.3 peptide phosphorylated at Ser173. Three separate trials, each with different uterine extracts from WT and irs1 K/K uteri, were used for the in situ histone phosphorylation experiments.
Statistical analysis
Statistical significance was determined by the Student's t-test; two-sided P%0 . 05 was considered statistically significant.
Results

IGF1 is required for E 2 -induced IRS-1 activation
Since we intended to use the irs1 K/K mice to compromise the IGF1R signaling pathway, it was important to ascertain at the outset that the IRS-1 docking protein requires IGF1 for activation of PI3K in response to E 2 . To demonstrate this, ovariectomized female WT and igf1 K/K mice were treated with E 2 (6 h), and the immunoprecipitates of IRS-1 from uterine epithelial extracts were evaluated for the PI3K regulatory subunit (p85). As shown in Fig. 1 , the immunoprecipitates of uterine IRS-1 from WT mice (lanes 1-4) revealed the expected increased association of p85 as a result of hormone treatment. In contrast, uterine IRS-1 from hormone-treated igf1 K/K mice (lanes 5-9) was not associated with p85. These findings indicate that the IGF1 ligand is a required intermediate for estrogens to activate IRS-1 and stimulate binding of p85 to IRS-1 in the uterus. In addition, these data rule out the participation of another IGF1R ligand, e.g. IGF2, that might function in the absence of IGF1 to stimulate the activation of IGF1R and IRS-1 (Osborne et al. 1989) .
Since IGF1 was critical for E 2 -induced activation of uterine IRS-1, mice with an IRS-1 null mutation could provide insights as to the importance of an IGF1/IGF1R/IRS-1 pathway in the proliferative response of uterine epithelial cells to E 2 . In order to determine this, ovariectomized adult irs1 K/K and WT (irs1 C/C ) female mice were treated with E 2 , and the uterine epithelium was examined for the proportion of cells in the S phase and in the mitosis. The proliferative response of the uterine epithelial cells to E 2 in the adult mouse is considered to begin with a drastic shortening of the G 1 -S
IRS-1 Figure 1 Binding of the PI3K regulatory subunit (p85) to uterine IRS-1 in wild-type (WT) and igf1 K/K mice treated with estradiol. Ovariectomized mice were treated with estradiol (E 2 ) or vehicle (C, control), and uterine epithelial extracts were obtained 6 h later. Aliquots of the extracts were incubated with anti-IRS-1 antiserum.
Immunoprecipitates were separated by SDS-7 . 5% PAGE and then immunoblotted with anti-p85 antiserum (upper panel) or anti-IRS-1 antiserum (lower panel). Other details of the treatment, extraction, and immunoblotting procedures are described in Materials and Methods. Each lane represents analyses of a different animal.
transition rate. The epithelial cells exhibit a near-synchronous wave of DNA synthesis beginning about 10 h after hormone treatment; this is followed by mitosis that peaks around 20-24 h. To identify cells in the S phase, BrdU was injected into animals that were previously treated with E 2 16 h earlier. Fig. 2B ). These data suggest that the IRS-1 null mutation affects the rate of transit of uterine epithelial cells through G 2 /M without impairing recruitment of cells into G 1 /S in response to E 2 . The effects obtained with the irs1 K/K mice with regard to hormone stimulation of the uterine epithelial cell cycle are similar to that reported previously for igf1 K/K mice (Adesanya et al. 1999) . In both cases, the null mutation affected the number of cells in mitosis but not the cells in the S phase. This functional overlap indicates that IGF1 and IRS-1 are part of the same signaling pathway that mediates hormonal stimulation of mitosis of cells in the uterine epithelium. The decrease in the number of mitotic figures observed at 22 h after E 2 treatment in irs1 K/K mice could not be explained by a difference in apoptosis. Evaluation of uterine sections at this time point for detection of fragmented DNA in situ end labeling showed no detectable apoptosis in the epithelium of WT or irs1 K/K mutant mice (data not shown).
The IRS-1 null mutation reduces the E 2 -induced increase in cdk1 (p34) protein but not in mRNA The significant decrease in hormone-induced mitosis in the uterine epithelium of irs1 K/K mice prompted us to consider an effect of the mutation on the major mitotic kinase cdk1. In the mammal, cdk1 kinase is poorly expressed in normal quiescent cells but accumulates during the S phase and peaks during the G 2 and M phases of the cell cycle (Kim et al. 1992 , Loyer et al. 1994 . As shown in Fig. 3A , microarray analysis of WT mouse uterine RNA reveals that the level of cdk1 transcripts increases markedly by 24 h after treatment with E 2 , whereas the level of cdk2 transcripts was essentially invariate during this period. The influence of E 2 on uterine cdk1 A B Figure 3 Changes in uterine cdk1 transcripts in wild-type and irs1 K/K mice after treatment with estradiol. (A) Total RNA was isolated from whole uteri of C57BL/6 (ovariectomized) mice at the indicated time points after treatment with estradiol. The plots compare the estradiol-induced fold changes in uterine gene expression of cdk1 against that of cdk2, as determined by microarray analyses. Details of the microarray are described in Materials and Methods. The plots were constructed from values given at the website in Hewitt et al. (2003) . (B) Total RNA was isolated from whole uteri of ovariectomized wild-type and irs1 K/K mice before and after treatment with estradiol. cDNA was prepared from 1 mg RNA and used for quantitative real-time PCR. Quantitation was made by the comparative C t method with actin as the endogenous reference gene. After calculating the C t (cdk1 minus actin), the values (C t ) were determined relative to that for untreated wild types. Each bar represents the meanGS.D.; n is the number of mice used in each group. Note that the mean value for the untreated IRS-1 (KO) was !1 . 0. Cdk1 transcript level was increased in wild-type (WT) and KO animals 24 h after hormone treatment; the value for KO (24 h) was significantly greater than that of WT (24 h) at P!0 . 05. Further details of the procedures and primer sequences are described in Materials and Methods. IGF1 pathway stimulates cdk1 kinase in uterus . M P WALKER and others 229 mRNA in WT mice was compared with that of irs1 K/K by quantitative PCR analyses using the comparative (C t ) method with actin as the reference gene. As shown in Fig. 3B , cdk1 transcripts increased in both the groups by 24 h after estrogen treatment. Interestingly, the level of uterine cdk1 mRNA in the IRS-1 null mutants was significantly greater (P!0 . 05) than that of the WT mice at this time point.
To compare the levels of cdk1 protein, the extracts of WT and mutant uterine epithelium were prepared at various time points after hormone treatment and evaluated by immunoblotting. In accordance with the microarray and quantitative PCR data, cdk1 (p34) protein in the quiescent uterine epithelium of ovariectomized mice (time 0), WT or irs1
, was below the level of detection (Fig. 4A) . When mice were treated with E 2 , uterine cdk1 increased and could be readily detected by 18 h in WT mice. In contrast, the uterine cdk1 abundance in irs1 K/K (KO) mice was generally much less than that observed in WTs at the corresponding intervals after hormone treatment (Fig. 4A) . In the four trials that analyzed the extracts from uteri obtained 24 h after estrogen treatment, the levels of cdk1 protein in mutants were significantly less (P!0 . 005) than that of WTs: KO (0 . 41G0 . 09, meanGS.D.) versus WT (1 . 16G0 . 14, meanGS.D.); KO/WT Z0 . 35 (Fig. 4B ).
For both WTs and mutants, the level of hormone-induced cdk1 was highest at the 30-h time point, which is after peak mitosis in this model. It is not known whether treatment with E 2 alone ('unopposed') favors this pattern, which might differ considerably from that of the intact female exposed to sequential cycles of estrogens and progestins. Levels of cdk2 (p33) kinase, which forms a heterodimer with cyclin A or cyclin E, were also examined in the uterine extracts of WT and irs1 K/K mice treated with hormone. As shown in Fig. 4  (upper panel) , cdk2, in contrast to cdk1, was detected in the extracts before and after hormone treatment. Hormone treatment did not elevate uterine cdk2 protein levels, which is in accordance with the microarray findings (Fig. 3A) . The discrepancy observed for cdk1 in WT and irs1 K/K mice was not apparent for cdk2.
The stimulation of AKT phosphorylation and cyclin B-associated kinase by E 2 is reduced in the irs1 K/K mutant Since hormone-induced mitosis was inhibited by the irs1
null mutants, we wanted to resolve whether the mutation compromised mitotic kinase activity. Cdk1 acquires the potential to become a mitotic kinase in mammalian cells when bound to cyclin B (Meijer et al. 1989) . It is possible that the observed reduction in cdk1 (protein) in mutants prevented accumulation of enough mitotic kinase for mitosis. Alternatively, the mutation might affect posttranslational changes that regulate cdk1. Activation and inhibition of cdk1 kinase are known to occur by phosphorylation and dephosphorylation of specific sites, and it is likely that some of these modifications are integrated with growth factor pathways. The activation of AKT (Ser473 phosphorylation) can be demonstrated in our experimental model, as shown by the timecourse study in Fig. 5 . AKT phosphorylation is clearly evident in the extracts from WTuterine epithelium obtained at 12 and 18 h following E 2 treatment. Based on densitometric scans obtained at the 12-h time point, the p-AKT/AKT in irs1 Fig. 5 , the p-AKT/AKT KO/WT ratios at 18 and 24 h after hormone treatment were similar to that reported at 12 h (data not shown). After 24 h, the level of AKT phosphorylation was very weak in both the groups (Fig. 5 ). These findings support that an IRS-1-dependent pathway is utilized for the hormonal activation of uterine epithelial AKT. Other (non-IRS-1) signaling pathways probably account for the phosphorylation of AKT observed in mutant animals.
To determine whether the IRS-1 null mutation can affect mitotic kinase activity, uterine cyclin B-associated kinase Time-course analyses of cdk1 and cdk2 (immunoreactivity) in uterine epithelial extracts of wild-type and irs1 K/K mice. Ovariectomized wild-type (WT) and irs1 K/K (KO) mutant mice were treated with estradiol, and uterine epithelial extracts were obtained at the time points indicated. Mice at the 0 time point did not receive hormone. Proteins (w30 mg) in aliquots from the extracts were separated by SDS-PAGE and immunoblotted for cdk1 or cdk2. Further details of the extraction and immunoblotting are described in Materials and Methods. In (A), immunoblots of uterine cdk1 and cdk2 are compared for up to 30 h after estradiol treatment. The results are representative of six different trials. Extracts for each trial (time course) were prepared on separate days; each lane represents an extract from one mouse uterus. In (B), immunoblots of cdk1 from wild-type (WT) and irs1 K/K (KO) mouse uterine extracts are compared. All the extracts were obtained from uteri 24 h after hormone treatment. Extracts from each of the four pairs of blots (WT versus KO) were prepared on different days; each lane represents an extract from one mouse uterus. Cytokeratin 18 (ck18), an epithelial marker, was a loading control. As determined by densitometry, KO cdk1 levels (0 . 41G0 . 09, meanGS.D.) were significantly less (P!0 . 005) than that of WT (1 . 16G0 . 14, meanGS.D.); KO/WTZ0 . 35. activity was examined for up to 48 h following treatment of the mice with E 2 . The phosphorylation of the histone H1 (exogenous) substrate was clearly evident at 20 h after hormone treatment in WT samples; however, much less kinase activity was observed at 48 h (Fig. 6A) . This temporal pattern is in keeping with the importance of cdk1/cyclin B kinase activity for entry into the mitotic phase of the cell cycle (Lew & Kornbluth 1996) . The corresponding time-course study with samples from irs1 K/K uteri revealed much less phosphorylation of histone H1 than that obtained with WT samples. As determined by phosphoimaging, the cyclin B-associated kinase activity at 20 h after E 2 treatment in irs1 K/K samples (1 . 25G0 . 17!10 4 , meanGS.D.) was significantly less (P!0 . 005) than that of WT samples (3 . 16G0 . 22!10 4 , meanGS.D.); KO/WTZ0 . 38. This effect of the IRS-1 null mutation on hormonal activation of cyclin B-associated kinase activity was not observed with cyclin A-associated kinase activity. As shown in Fig. 6B , the 32 P-labeling of the histone H1 substrate by kinase associated with cyclin A precipitates was comparable in the extracts from WT and irs1 K/K mice. Immunoblots were made of cyclin B and cyclin A in the extracts obtained after 20 h. The amount of each cyclin appeared comparable in WT and irs1 K/K samples (Fig. 6B) . Therefore, it is unlikely that the disparity between hormone-induced cyclin B-associated kinase activity in irs1 K/K and WT uteri could be explained by lower cyclin B levels.
Phosphorylation of H1 histone during mitosis entry is considered a downstream event of cdk1/cyclin B (Langan et al. 1989) . Therefore, we examined the effect of the IRS-1 null mutation on hormone-induced phosphorylation of endogenous H1 histone with a phospho-specific (pThr18) antiserum to a cognate sequence of phospho (Thr18) mouse histone H1.3. As shown in Fig. 6C , three major bands corresponding to H1 isoforms were detected in the acid extracts of isolated uterine nuclei from WT and irs1 K/K mice. Twenty hours following hormone treatment, an immunoreactive band was observed in WT extracts that comigrated with the H1.3/H1.4 isoforms. In contrast, hormone-induced phosphorylation of these isoforms isolated from irs1 K/K mice was much less than that observed with WT mice. This finding suggests that the activation of the IGF1/IRS-1 pathway by E 2 can result in phosphorylation of endogenous histone. 
Discussion
The use of the whole animal as an experimental model is important in accurately resolving the qualitative and quantitative responses of hormones. Cell cultures are generally inappropriate for studying estrogen-stimulated proliferation because of the requirement for normal epithelial/stromal interactions (Cooke et al. 1997 (Cooke et al. , 2002 . Cell cultures may not only be refractory to hormone action but also impose artifacts as a consequence of immortalization, high rate of cell turnover, or inappropriate activation of signaling pathways. This later aspect is particularly important in the present investigation where we are trying to link an E 2 -induced growth factor pathway with components of the cell cycle.
Since E 2 treatment of ovariectomized igf1 K/K female mice failed to stimulate binding of p85 (PI3K) to IRS-1 in uterine epithelial cells, mice with the IRS-1 null mutation should reflect the importance of this adaptor protein as well as of IGF1 receptor signaling in response to E 2 . Earlier studies in this laboratory showed that PI3K was the only SH2 protein that bound to uterine IRS-1 following E 2 treatment (Richards et al. 1998) . Thus, the absence of IRS-1 shouldbarring any adaptive changes in the null mutant -selectively deprive the uterine epithelial cell of that pool of PI3K that becomes catalytically active by binding to IRS-1 as a consequence of E 2 stimulation of the IGF1 receptor pathway. It was previously reported that stimulation of PI3K activity by IGF1 in irs1 K/K mouse embryonic fibroblasts was reduced by 70% when compared with that of irs1 C/C cells (Bruning et al. 1997) . Mouse embryonic cells, along with uterine cells, contain IRS-2, which can also bind and activate PI3K (Sun et al. 1995) . This IRS isoform does not functionally supplant IRS-1 in the embryonic fibroblasts. In addition, after E 2 treatment, uterine IRS-2 is degraded through an IGFstimulated, proteasome-dependent pathway, while levels of IRS-1 remain essentially unchanged (Richards et al. 2001) .
The IRS-1 null mutation did not significantly alter the fraction of uterine epithelial cells undergoing DNA synthesis in response to E 2 ; however, this mutation markedly reduced the fraction of cells undergoing mitosis. These data are very similar to the cytokinetic response to E 2 in uterine cells of igf1 K/K mice (Adesanya et al. 1999) . In a broad sense, these findings indicate that a growth factor pathway can regulate a specific stage, e.g. mitosis, of the cell cycle. Thus, we can propose that an IGF1R/IRS-1/PI3K pathway stimulates the rate of mitosis in the uterine epithelium in response to estrogens. There are several reports where cell lines were used to demonstrate that a signaling pathway downstream from PI3K/AKT functions in the G 2 /M transition of the cell cycle. In synchronized HeLa or MDCK cells, AKT activity was maximal during the G 2 /early M phase and then dropped precipitously as cells completed mitosis (Shtivelman et al. 2002) . Inhibition of PI3K in these cells prevents the activation of cyclin B-associated kinase and elicits G 2 arrest that can be abolished by activated AKT. In HEK293 cells, inhibition of PI3K also induces a G 2 cell cycle arrest that could be alleviated by activated AKT. Mouse embryonic fibroblasts with an AKT1 null mutation revealed a delayed transition from G 2 /M to G 1 (Kandel et al. 2002) . In this study, the reduction in PI3K/AKT activation caused by the IRS-1 null mutation apparently led to a loss of specific stimulation of the G 2 /M transition. The component(s) of the cell cycle regulated by the hormonally stimulated IRS-1/PI3K/AKT that would specifically influence the mitotic phase is unknown.
In accordance with the reduced rate of E 2 -induced mitosis in uterine cells of irs1 K/K mice, there was a marked reduction in cyclin B-associated kinase activity. Other cdks cannot supplant the function of cdk1 as a mitotic kinase in mammalian cells (Nurse 1990 , Nigg 1993 . On the other hand, cdk1 can associate with A-and B-type cyclins in mammalian cells to phosphorylate histone H1 (Loyer et al. 1994 , Swank et al. 1997 . Since levels of cyclin A, cdk2, and cyclin A-associated H1 kinase activity were not affected by the IRS-1 null mutation, it is likely that cyclin A predominantly functions in uterine cells as a complex with cdk2. This would favor the notion that IGF1R signaling in these cells targets cdk1, and not other cdks, such as cdk2. The level of cdk1 in the IRS-1 null mutants prior to mitosis was less than that in WTs, which could delay the formation of the threshold concentration of the mitotic kinase (heterodimer). Since the lower levels of cdk1 protein could not be explained by a corresponding decrease in transcript, altered signaling in the mutant might have reduced translation or half-life of cdk1. Earlier studies showed that IRS-1 and PI3K were required for insulin to stimulate eIF-4E/4E-BP-1 phosphorylation and translation in cultured cells (Mendez et al. 1996) . Using phospho-specific antisera, we demonstrated that the translation effectors mechanistic target of rapamycin, tuberin, 4E-BP1, eIF-4E, p70S6 kinase, and glycogen synthase kinase 3 are activated in response to E 2 ; however, we could not demonstrate an effect of the IRS-1 null mutation on specific phosphorylation of these translational components (data not shown). To our knowledge, this specific effect of the IGF1R signaling on cdk1 protein levels has not been previously reported. One study did suggest that translational control of cdk1 (p34 cdc2 ) was associated with meiotic competence of mouse oocytes; incompetent oocytes have abundant cdk1 mRNA but low levels of cdk1 protein (deVantery et al. 1997 ). Our experimental model may have allowed us to identify changes in cell cycle components that do not occur or are obscured by most cells in culture. With many immortalized cell lines, for instance, the cdk1 protein is expressed at all stages of the cell cycle (McGowan et al. 1990 , Welch & Wang 1992 , Draetta & Beach 1998 . However, there are aspects of cdk1 transcripts in mammalian cell cultures that overlap with those observed in animal studies. For instance, cdk1 transcription in HeLa cells is elevated in the S and G 2 phases and low in the G 1 phase of the cell cycle, based on nuclear run-on assays (Dalton 1992) . Likewise, other studies with HeLa cells revealed that the abundance of cdk1 mRNA and rate of synthesis of cdk1 protein (p34) increase dramatically as the cells pass through S/G 2 (Welch & Wang 1992) .
Since the KO/WT for p-AKT/AKT was similar at different times (12, 18, and 24 h) after hormone treatment, it is likely that the IRS-1 null mutation does not affect the rate of p-AKT dephosphorylation at Ser473. During the period when uterine AKT phosphorylation was elevated in WT and irs1 K/K mice, AKT was essentially unchanged from that of untreated mice; the increased level of AKTobserved after 24 h following treatment with E 2 is in keeping with the known increase in AKT transcripts in response to this hormone (Hewitt et al. 2003) . It was reasonable to expect in our model that the IRS-1 null mutation would cause a pronounced reduction in AKT activation. Previous reports suggest that enzymes that regulate phosphorylation and activity of the mitotic kinase are proximal targets of AKT. For instance, phosphorylation at Thr14 and Tyr15 of cdk1 by Myt1, a member of the Wee family of kinases, inhibits the kinase activity of cdk1 (Mueller et al. 1995) . In a study with starfish oocytes, it was shown that AKT, acting downstream from PI3K, phosphorylates Myt1 and downregulates its activity, which favors the meiotic G 2 /M phase transition (Okumura et al. 2002) . A related study showed that AKT can phosphorylate Wee 1 in 293T or HeLa cells, which promotes cytoplasmic localization at the kinase (by binding to 14-3-3q), and G 2 /M cell progression (Katayama et al. 2005 ). Thus, it is possible that a deficient PI3K/AKT signaling pathway in the IRS-1 null mutants increases phosphorylation at Thr14/Tyr15 of cdk1 and thereby compromises its kinase activity. Alternatively, AKT might also be activating cdc25C, which dephosphorylates Thr14/Tyr15 of cdk1. Inhibition of PI3K by LY294002 in HeLa cells delays hyperphosphorylation of cdc25C and cells entering mitosis (Dangi et al. 2003) . However, it is still not known whether a PI3K/AKT pathway is activating for cdc25C, directly or indirectly. In another study, wortmannin, a potent inhibitor of PI3K, partially inhibited cyclin B translation and inhibited dephosphorylation of the tyrosine (inhibitory) site of cdk1 of sea urchin oocytes (Salaün et al. 2002) . In the later study, the effects of wortmannin on cyclin B synthesis (triggered by fertilization) were also correlated with the effects of this compound on cap-dependent translation machinery, which included 4E-BP/eIF-4E dissociation. AKT facilitates the G 2 /M phase transition of mouse PC12 neuronal cells (Lee et al. 2005) . Stable expression of a dominant negative form of AKT suppressed expression of both cdk1 and cyclin B1 at the mRNA and protein levels without affecting the cyclin A or cdk2 protein levels. A constitutively active form of AKT (myristoylated AKT) elevated cyclin B and cdk1 mRNA and protein levels and could override cell growth arrest at G 2 /M (induced by etoposide).
The present finding that the hormone-induced phosphorylation of an endogenous histone H1 isoform in WTs clearly exceeded that of irs1 K/K mice is in accordance with the observed decrease of cyclin B-associated kinase activity in the mutant animals. The purified cdk1/cyclin B heterodimer phosphorylates specific sites on histone H1 in vitro (Swank et al. 1997) . Earlier studies had also provided evidence to show that the cdks are the major in vivo kinases for H1 at cell cycle transitions with cdk1 implicated as the G 2 kinase for H1 (Langan et al. 1989) . The phosphorylation of histone H1 in vivo by a cdk is considered to destabilize H1-chromatin interactions and, thereby, facilitate a more open chromatin structure (Contrera et al. 2003) . Thus, by regulating cyclin B-associated kinase activity an IGF1R/IRS-1/PI3K-stimulated signaling cascade mediates hormonal effects on the state of chromatin condensation. A query to consider for postmenopausal females receiving prolonged exposure to estrogens is whether the perturbation of chromatin structure by this signaling pathway facilitates genomic instability and increased risk of endometrial cancer (Enders & Maude 2006) .
Our cumulative findings support that the stimulation of uterine epithelial cell proliferation by E 2 is mediated by an IGF1/IRS-1/PI3K/AKT pathway, and that this pathway targets the mitotic kinase cdk1/cyclin B. A specific goal of future work should determine whether impairment of AKT activity by the IRS-1 null mutation affects the activity of enzymes or other proteins that regulate posttranslational changes or catalytic activity of cdk1. Other cell populations might have mechanisms to regulate mitotic kinase activity that are similar to or overlap with those observed in this study. In a broad sense, our experimental findings are probably part of a more general phenomenon, where individual growth factors exert stage-specific regulation of the cell cycle by activating or suppressing specific cyclin-associated kinases.
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